Clareo Health | Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)
Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Basel, Switzerland
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
stable clinical state (at least 4 weeks after treatment with corticoids, when there was a relapse)
Provision of written informed consent and ability to be compliant with the schedule of assessments of the present study
You may not be if
additionally patients with movable metal implants, e.g. pace-maker, stents, deep brain stimulators are excluded; (patients with jaw- or bone-fixed metal implants can be included)
